| Date Filed | Type | Description |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/02/2023 |
4
| MILANO VINCENT (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 680 shares
@ $8.27, valued at
$5.6k
|
|
| 06/02/2023 |
4
| LEVIN ALAN G (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 1,360 shares
@ $8.27, valued at
$11.2k
|
|
| 06/02/2023 |
4
| HEGGIE THERESA (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 680 shares
@ $8.27, valued at
$5.6k
|
|
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
4
| Thackray Helen M. (Chief R&D Officer) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Sold 7,000 shares
@ $8.29, valued at
$58k
|
|
| 03/23/2023 |
4
| Stonehouse Jon P (President & CEO) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Exercised 31,055 options to buy
@ $3.22, valued at
$100k
|
|
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/02/2023 |
4
| MILANO VINCENT (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 635 shares
@ $8.85, valued at
$5.6k
|
|
| 03/02/2023 |
4
| INGRAM ROBERT ALEXANDER (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 2,259 shares
@ $8.85, valued at
$20k
|
|
| 03/02/2023 |
4
| HEGGIE THERESA (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 635 shares
@ $8.85, valued at
$5.6k
|
|
| 03/02/2023 |
4
| LEVIN ALAN G (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 1,271 shares
@ $8.85, valued at
$11.2k
|
|
| 02/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 10% stake in BioCryst Pharmaceuticals, Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/02/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|